Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups.
Identifieur interne : 002010 ( PubMed/Checkpoint ); précédent : 002009; suivant : 002011Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups.
Auteurs : G M Leung [États-Unis] ; W W Lim ; L-M Ho ; T-H Lam ; A C Ghani ; C A Donnelly ; C. Fraser ; S. Riley ; N M Ferguson ; R M Anderson ; A J HedleySource :
- Epidemiology and infection [ 0950-2688 ] ; 2006.
Descripteurs français
- KwdFr :
- MESH :
- analyse : Immunoglobuline G.
- immunologie : Syndrome respiratoire aigu sévère, Virus du SRAS.
- pathogénicité : Virus du SRAS.
- Donneurs de sang, Géographie, Humains, Personnel de santé, Production d'anticorps, Études séroépidémiologiques.
English descriptors
- KwdEn :
- MESH :
- chemical , analysis : Immunoglobulin G.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- pathogenicity : SARS Virus.
- Antibody Formation, Blood Donors, Geography, Health Personnel, Humans, Seroepidemiologic Studies.
Abstract
We systematically reviewed the current understanding of human population immunity against SARS-CoV in different groups, settings and geography. Our meta-analysis, which included all identified studies except those on wild animal handlers, yielded an overall seroprevalence of 0.10% [95% confidence interval (CI) 0.02-0.18]. Health-care workers and others who had close contact with SARS patients had a slightly higher degree of seroconversion (0.23%, 95% CI 0.02-0.45) compared to healthy blood donors, others from the general community or non-SARS patients recruited from the health-care setting (0.16%, 95% CI 0-0.37). When analysed by the two broad classes of testing procedures, it is clear that serial confirmatory test protocols resulted in a much lower estimate (0.050%, 95% CI 0-0.15) than single test protocols (0.20%, 95% CI 0.06-0.34). Potential epidemiological and laboratory pitfalls are also discussed as they may give rise to false or inconsistent results in measuring the seroprevalence of IgG antibodies to SARS-CoV.
DOI: 10.1017/S0950268805004826
PubMed: 16490123
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:16490123Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups.</title>
<author><name sortKey="Leung, G M" sort="Leung, G M" uniqKey="Leung G" first="G M" last="Leung">G M Leung</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Community Medicine, University of Hong Kong, Pokfulam, Hong Kong, ChinaTakemi Program, Harvard School of Public Health, Boston, MA, USA. gmleung@hkucc.hk</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Community Medicine, University of Hong Kong, Pokfulam, Hong Kong, ChinaTakemi Program, Harvard School of Public Health, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lim, W W" sort="Lim, W W" uniqKey="Lim W" first="W W" last="Lim">W W Lim</name>
</author>
<author><name sortKey="Ho, L M" sort="Ho, L M" uniqKey="Ho L" first="L-M" last="Ho">L-M Ho</name>
</author>
<author><name sortKey="Lam, T H" sort="Lam, T H" uniqKey="Lam T" first="T-H" last="Lam">T-H Lam</name>
</author>
<author><name sortKey="Ghani, A C" sort="Ghani, A C" uniqKey="Ghani A" first="A C" last="Ghani">A C Ghani</name>
</author>
<author><name sortKey="Donnelly, C A" sort="Donnelly, C A" uniqKey="Donnelly C" first="C A" last="Donnelly">C A Donnelly</name>
</author>
<author><name sortKey="Fraser, C" sort="Fraser, C" uniqKey="Fraser C" first="C" last="Fraser">C. Fraser</name>
</author>
<author><name sortKey="Riley, S" sort="Riley, S" uniqKey="Riley S" first="S" last="Riley">S. Riley</name>
</author>
<author><name sortKey="Ferguson, N M" sort="Ferguson, N M" uniqKey="Ferguson N" first="N M" last="Ferguson">N M Ferguson</name>
</author>
<author><name sortKey="Anderson, R M" sort="Anderson, R M" uniqKey="Anderson R" first="R M" last="Anderson">R M Anderson</name>
</author>
<author><name sortKey="Hedley, A J" sort="Hedley, A J" uniqKey="Hedley A" first="A J" last="Hedley">A J Hedley</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:16490123</idno>
<idno type="pmid">16490123</idno>
<idno type="doi">10.1017/S0950268805004826</idno>
<idno type="wicri:Area/PubMed/Corpus">002338</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002338</idno>
<idno type="wicri:Area/PubMed/Curation">002338</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002338</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002010</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002010</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups.</title>
<author><name sortKey="Leung, G M" sort="Leung, G M" uniqKey="Leung G" first="G M" last="Leung">G M Leung</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Community Medicine, University of Hong Kong, Pokfulam, Hong Kong, ChinaTakemi Program, Harvard School of Public Health, Boston, MA, USA. gmleung@hkucc.hk</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Community Medicine, University of Hong Kong, Pokfulam, Hong Kong, ChinaTakemi Program, Harvard School of Public Health, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lim, W W" sort="Lim, W W" uniqKey="Lim W" first="W W" last="Lim">W W Lim</name>
</author>
<author><name sortKey="Ho, L M" sort="Ho, L M" uniqKey="Ho L" first="L-M" last="Ho">L-M Ho</name>
</author>
<author><name sortKey="Lam, T H" sort="Lam, T H" uniqKey="Lam T" first="T-H" last="Lam">T-H Lam</name>
</author>
<author><name sortKey="Ghani, A C" sort="Ghani, A C" uniqKey="Ghani A" first="A C" last="Ghani">A C Ghani</name>
</author>
<author><name sortKey="Donnelly, C A" sort="Donnelly, C A" uniqKey="Donnelly C" first="C A" last="Donnelly">C A Donnelly</name>
</author>
<author><name sortKey="Fraser, C" sort="Fraser, C" uniqKey="Fraser C" first="C" last="Fraser">C. Fraser</name>
</author>
<author><name sortKey="Riley, S" sort="Riley, S" uniqKey="Riley S" first="S" last="Riley">S. Riley</name>
</author>
<author><name sortKey="Ferguson, N M" sort="Ferguson, N M" uniqKey="Ferguson N" first="N M" last="Ferguson">N M Ferguson</name>
</author>
<author><name sortKey="Anderson, R M" sort="Anderson, R M" uniqKey="Anderson R" first="R M" last="Anderson">R M Anderson</name>
</author>
<author><name sortKey="Hedley, A J" sort="Hedley, A J" uniqKey="Hedley A" first="A J" last="Hedley">A J Hedley</name>
</author>
</analytic>
<series><title level="j">Epidemiology and infection</title>
<idno type="ISSN">0950-2688</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibody Formation</term>
<term>Blood Donors</term>
<term>Geography</term>
<term>Health Personnel</term>
<term>Humans</term>
<term>Immunoglobulin G (analysis)</term>
<term>SARS Virus (immunology)</term>
<term>SARS Virus (pathogenicity)</term>
<term>Seroepidemiologic Studies</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Donneurs de sang</term>
<term>Géographie</term>
<term>Humains</term>
<term>Immunoglobuline G (analyse)</term>
<term>Personnel de santé</term>
<term>Production d'anticorps</term>
<term>Syndrome respiratoire aigu sévère (immunologie)</term>
<term>Virus du SRAS (immunologie)</term>
<term>Virus du SRAS (pathogénicité)</term>
<term>Études séroépidémiologiques</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Immunoglobulin G</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Immunoglobuline G</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Antibody Formation</term>
<term>Blood Donors</term>
<term>Geography</term>
<term>Health Personnel</term>
<term>Humans</term>
<term>Seroepidemiologic Studies</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Donneurs de sang</term>
<term>Géographie</term>
<term>Humains</term>
<term>Personnel de santé</term>
<term>Production d'anticorps</term>
<term>Études séroépidémiologiques</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We systematically reviewed the current understanding of human population immunity against SARS-CoV in different groups, settings and geography. Our meta-analysis, which included all identified studies except those on wild animal handlers, yielded an overall seroprevalence of 0.10% [95% confidence interval (CI) 0.02-0.18]. Health-care workers and others who had close contact with SARS patients had a slightly higher degree of seroconversion (0.23%, 95% CI 0.02-0.45) compared to healthy blood donors, others from the general community or non-SARS patients recruited from the health-care setting (0.16%, 95% CI 0-0.37). When analysed by the two broad classes of testing procedures, it is clear that serial confirmatory test protocols resulted in a much lower estimate (0.050%, 95% CI 0-0.15) than single test protocols (0.20%, 95% CI 0.06-0.34). Potential epidemiological and laboratory pitfalls are also discussed as they may give rise to false or inconsistent results in measuring the seroprevalence of IgG antibodies to SARS-CoV.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16490123</PMID>
<DateCompleted><Year>2006</Year>
<Month>04</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0950-2688</ISSN>
<JournalIssue CitedMedium="Print"><Volume>134</Volume>
<Issue>2</Issue>
<PubDate><Year>2006</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Epidemiology and infection</Title>
<ISOAbbreviation>Epidemiol. Infect.</ISOAbbreviation>
</Journal>
<ArticleTitle>Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups.</ArticleTitle>
<Pagination><MedlinePgn>211-21</MedlinePgn>
</Pagination>
<Abstract><AbstractText>We systematically reviewed the current understanding of human population immunity against SARS-CoV in different groups, settings and geography. Our meta-analysis, which included all identified studies except those on wild animal handlers, yielded an overall seroprevalence of 0.10% [95% confidence interval (CI) 0.02-0.18]. Health-care workers and others who had close contact with SARS patients had a slightly higher degree of seroconversion (0.23%, 95% CI 0.02-0.45) compared to healthy blood donors, others from the general community or non-SARS patients recruited from the health-care setting (0.16%, 95% CI 0-0.37). When analysed by the two broad classes of testing procedures, it is clear that serial confirmatory test protocols resulted in a much lower estimate (0.050%, 95% CI 0-0.15) than single test protocols (0.20%, 95% CI 0.06-0.34). Potential epidemiological and laboratory pitfalls are also discussed as they may give rise to false or inconsistent results in measuring the seroprevalence of IgG antibodies to SARS-CoV.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leung</LastName>
<ForeName>G M</ForeName>
<Initials>GM</Initials>
<AffiliationInfo><Affiliation>Department of Community Medicine, University of Hong Kong, Pokfulam, Hong Kong, ChinaTakemi Program, Harvard School of Public Health, Boston, MA, USA. gmleung@hkucc.hk</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lim</LastName>
<ForeName>W W</ForeName>
<Initials>WW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ho</LastName>
<ForeName>L-M</ForeName>
<Initials>LM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lam</LastName>
<ForeName>T-H</ForeName>
<Initials>TH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ghani</LastName>
<ForeName>A C</ForeName>
<Initials>AC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Donnelly</LastName>
<ForeName>C A</ForeName>
<Initials>CA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Fraser</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Riley</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ferguson</LastName>
<ForeName>N M</ForeName>
<Initials>NM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Anderson</LastName>
<ForeName>R M</ForeName>
<Initials>RM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hedley</LastName>
<ForeName>A J</ForeName>
<Initials>AJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym>
<Agency>Wellcome Trust</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D017418">Meta-Analysis</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Epidemiol Infect</MedlineTA>
<NlmUniqueID>8703737</NlmUniqueID>
<ISSNLinking>0950-2688</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001782" MajorTopicYN="N">Blood Donors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005843" MajorTopicYN="N">Geography</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006282" MajorTopicYN="N">Health Personnel</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2005</Year>
<Month>04</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2006</Year>
<Month>2</Month>
<Day>24</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2006</Year>
<Month>4</Month>
<Day>6</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2006</Year>
<Month>2</Month>
<Day>24</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16490123</ArticleId>
<ArticleId IdType="pii">S0950268805004826</ArticleId>
<ArticleId IdType="doi">10.1017/S0950268805004826</ArticleId>
<ArticleId IdType="pmc">PMC2870380</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2004 Dec;42(12):5885-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15583332</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 May 30;300(5624):1377-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12775826</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 Jun 20;300(5627):1961-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12766206</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 Jun 20;300(5627):1966-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12766207</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Jan;79(2):884-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15613317</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2005 Mar;75(3):463-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15648061</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2005 Mar;75(3):455-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15648064</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2003 May 1;187(9):1404-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12717621</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 Jul 31;349(5):508-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12890855</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 2003 Aug 29;331(5):991-1004</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12927536</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 May 17;361(9370):1701-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12767737</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2003 Sep;9(9):1037-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14519236</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Di Yi Jun Yi Da Xue Xue Bao. 2003 Oct;23(10):1085-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14559701</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2003 Oct 17;52(41):986-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14561956</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Oct 25;362(9393):1353-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14585636</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhonghua Jie He He Hu Xi Za Zhi. 2003 Oct;26(10):583-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14633437</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2003 Nov;9(11):1453-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14718090</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2004 Feb 15;189(4):642-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14767817</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2542-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14983045</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2004 Mar 12;303(5664):1666-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14752165</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2004 Feb;10(2):176-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15030679</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2004 Feb;10(2):249-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15030691</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2004 Mar 13;363(9412):841-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15031027</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2004 Apr;10(4):368-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15034574</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhonghua Yu Fang Yi Xue Za Zhi. 2004 Mar;38(2):81-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15061910</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2004 Apr 22;350(17):1731-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15102999</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2004 May;42(5):2306-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15131220</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2004 May;42(5):2351-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15131233</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhonghua Jie He He Hu Xi Za Zhi. 2004 Mar;27(3):151-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15130323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Med Genet. 2003 Sep 12;4:9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12969506</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2004 May 29;363(9423):1825; author reply 1826-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15172784</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2004 May 29;363(9423):1825; author reply 1826-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15172785</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2004 May 29;363(9423):1825-6; author reply 1826-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15172786</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2004 May 29;363(9423):1826; author reply 1826-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15172787</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2004 Jun;42(6):2629-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15184444</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Scand J Infect Dis. 2004;36(4):287-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15198186</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2004 Sep;10(9):1653-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15498170</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Control Clin Trials. 1986 Sep;7(3):177-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3802833</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Invest. 1994 Aug;23(4-5):313-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7959963</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Immunol. 1998;16:593-617</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9597143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Massachusetts</li>
</region>
</list>
<tree><noCountry><name sortKey="Anderson, R M" sort="Anderson, R M" uniqKey="Anderson R" first="R M" last="Anderson">R M Anderson</name>
<name sortKey="Donnelly, C A" sort="Donnelly, C A" uniqKey="Donnelly C" first="C A" last="Donnelly">C A Donnelly</name>
<name sortKey="Ferguson, N M" sort="Ferguson, N M" uniqKey="Ferguson N" first="N M" last="Ferguson">N M Ferguson</name>
<name sortKey="Fraser, C" sort="Fraser, C" uniqKey="Fraser C" first="C" last="Fraser">C. Fraser</name>
<name sortKey="Ghani, A C" sort="Ghani, A C" uniqKey="Ghani A" first="A C" last="Ghani">A C Ghani</name>
<name sortKey="Hedley, A J" sort="Hedley, A J" uniqKey="Hedley A" first="A J" last="Hedley">A J Hedley</name>
<name sortKey="Ho, L M" sort="Ho, L M" uniqKey="Ho L" first="L-M" last="Ho">L-M Ho</name>
<name sortKey="Lam, T H" sort="Lam, T H" uniqKey="Lam T" first="T-H" last="Lam">T-H Lam</name>
<name sortKey="Lim, W W" sort="Lim, W W" uniqKey="Lim W" first="W W" last="Lim">W W Lim</name>
<name sortKey="Riley, S" sort="Riley, S" uniqKey="Riley S" first="S" last="Riley">S. Riley</name>
</noCountry>
<country name="États-Unis"><region name="Massachusetts"><name sortKey="Leung, G M" sort="Leung, G M" uniqKey="Leung G" first="G M" last="Leung">G M Leung</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002010 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002010 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:16490123 |texte= Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:16490123" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |